The Medical journal of Australia · 2026
Costs of Delivering the Hep B PAST Model of Care in Remote Australia: A Retrospective Pre-Post Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Hoa, Nguyen Anh Le Tuan, Binks Paula, McKinnon Melita, Vintour-Cesar Emily, Wills Karen, Stephens Nicola, Cowie Benjamin, Davis Joshua S, Zhao Yuejen, Nihill Peter, Campbell Julie A, Palmer Andrew J, Davies Jane, de Graaff Barbara
Аннотация
OBJECTIVES: To estimate the direct medical costs of the Hep B Partnership Program (Hep B PAST) model of care compared with chronic hepatitis B (CHB) usual care from the health system perspective (Northern Territory (NT) Department of Health and the Commonwealth).
STUDY TYPE: Retrospective cohort study (2014-2023) that linked primary care with inpatient, emergency, outpatient and outreach datasets. Costs were applied using National Weighted Activity Units, the Pharmaceutical Benefits Scheme and NT Government costings. A pre- and post-implementation design from a health system perspective was applied, with costs in 2023 Australian dollars.
SETTING: Remote communities in the NT, Australia.
PARTICIPANTS: The cohort included all First Nations people living with CHB who were attending a clinic in a remote community that had consented to the Hep B PAST program, and who received care between 1 July 2014 and 31 May 2023.
MAIN OUTCOME MEASURES: Annual mean and median healthcare costs per contact and per individual across service types, with comparisons of annual mean costs per individual between pre- and post-Hep B PAST using partially overlapping t-tests.
RESULTS: Among 1063 First Nations individuals with CHB, annual median costs per individual were similar for usual care ($639 [interquartile range, $366-1156]) and Hep B PAST ($770 [interquartile range, $400-1272]); mean costs were also similar for usual care versus Hep B PAST ($1701 vs. $1970; p = 0.12). By service type, annual median costs were similar for inpatient services ($7777 vs. $7795), primary care ($327 vs. $302) and outpatient visits ($1985 vs. $1858), and higher for Hep B PAST for emergency services ($1339 vs. $1672) and outreach care ($373 vs. $746).
CONCLUSIONS: In remote First Nations communities, Hep B PAST was delivered with a modest increase in direct medical costs compared with usual care. These findings can be used to inform future cost-effective evaluations. Future cost savings from decreased hepatocellular carcinoma and liver failure were not included.
STUDY TYPE: Retrospective cohort study (2014-2023) that linked primary care with inpatient, emergency, outpatient and outreach datasets. Costs were applied using National Weighted Activity Units, the Pharmaceutical Benefits Scheme and NT Government costings. A pre- and post-implementation design from a health system perspective was applied, with costs in 2023 Australian dollars.
SETTING: Remote communities in the NT, Australia.
PARTICIPANTS: The cohort included all First Nations people living with CHB who were attending a clinic in a remote community that had consented to the Hep B PAST program, and who received care between 1 July 2014 and 31 May 2023.
MAIN OUTCOME MEASURES: Annual mean and median healthcare costs per contact and per individual across service types, with comparisons of annual mean costs per individual between pre- and post-Hep B PAST using partially overlapping t-tests.
RESULTS: Among 1063 First Nations individuals with CHB, annual median costs per individual were similar for usual care ($639 [interquartile range, $366-1156]) and Hep B PAST ($770 [interquartile range, $400-1272]); mean costs were also similar for usual care versus Hep B PAST ($1701 vs. $1970; p = 0.12). By service type, annual median costs were similar for inpatient services ($7777 vs. $7795), primary care ($327 vs. $302) and outpatient visits ($1985 vs. $1858), and higher for Hep B PAST for emergency services ($1339 vs. $1672) and outreach care ($373 vs. $746).
CONCLUSIONS: In remote First Nations communities, Hep B PAST was delivered with a modest increase in direct medical costs compared with usual care. These findings can be used to inform future cost-effective evaluations. Future cost savings from decreased hepatocellular carcinoma and liver failure were not included.